Pradaxa < sup > ® < /sup > (dabigatran etexilate) 150mg bid continues to be the only oral anticoagulant which showed superior ischaemic stroke reduction vs. warfarin in its pivotal study RE-LY < sup > ® < /sup > – Results of the ENGAGE AF-TIMI 48 trial published for edoxaban vs. warfarin do

Pradaxa < sup > ® < /sup > (dabigatran etexilate) 150mg bid continues to be the only oral anticoagulant which showed superior ischaemic stroke reduction vs. warfarin in its pivotal study RE-LY < sup > ® < /sup > – Results of the ENGAGE AF-TIMI 48 trial published for edoxaban vs. warfarin do
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news